Loading clinical trials...
Loading clinical trials...
necrotizing enterocolitis is a dangerous disease that may be fatal especially in preterm neonates, the early features of the disease are symptoms of feeding intolerance and interruption of the baby's feeding plan , so prophylactic measures at this stage may help to prevent its progression and its complications. N-acetyl cysteine is an FDA- approved drug and has many uses in different diseases and in different age groups including neonates, it has a mucolytic and anti-inflammatory and anti-oxidant effects that are believed to break the bacterial biofilm which enables it to stick to the intestinal wall and also decrease the intestinal wall inflammation, therefore enhance the intestinal barrier and decrease the chance of bacterial invasion.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Ain Shams university hospitals
Cairo, Egypt
Start Date
January 1, 2023
Primary Completion Date
March 30, 2024
Completion Date
March 30, 2024
Last Updated
January 12, 2024
100
ESTIMATED participants
oral n-acetyl cysteine
DRUG
placebo
OTHER
Lead Sponsor
Ain Shams University
NCT00747851
NCT03210831
NCT06727877
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions